{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T17:50:22Z","timestamp":1769277022860,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T00:00:00Z","timestamp":1666137600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100018998","name":"Ege University Research Foundation","doi-asserted-by":"publisher","award":["TGA-2019-20180"],"award-info":[{"award-number":["TGA-2019-20180"]}],"id":[{"id":"10.13039\/501100018998","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11686-022-00630-5","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T06:02:46Z","timestamp":1666159366000},"page":"1732-1739","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Effect of BTK Inhibitor Ibrutinib on Leishmania infantum Infection In Vitro"],"prefix":"10.1007","volume":"67","author":[{"given":"Ufuk","family":"Mert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Can","family":"M\u00fcft\u00fco\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevgi","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayg\u00fcl","family":"Sad\u0131qova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seray","family":"Toz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Ozbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3058-9971","authenticated-orcid":false,"given":"Ayse","family":"Caner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,19]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"815023","DOI":"10.1155\/2015\/815023","volume":"2015","author":"JPB de Menezes","year":"2015","unstructured":"de Menezes JPB, Guedes CES, de Oliveira Almeida Petersen AL et al (2015) Advances in development of new treatment for leishmaniasis. Biomed Res Int 2015:815023. https:\/\/doi.org\/10.1155\/2015\/815023","journal-title":"Biomed Res Int"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","volume":"392","author":"S Burza","year":"2018","unstructured":"Burza S, Croft SL, Boelaert M (2018) Leishmaniasis. Lancet 392:951\u2013970. https:\/\/doi.org\/10.1016\/S0140-6736(18)31204-2","journal-title":"Lancet"},{"key":"630_CR3","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1515\/pac-2018-1102","volume":"91","author":"RM Reguera","year":"2019","unstructured":"Reguera RM, P\u00e9rez-Pertejo Y, Guti\u00e9rrez-Corbo C et al (2019) Current and promising novel drug candidates against visceral leishmaniasis. Pure Appl Chem 91:1385\u20131404. https:\/\/doi.org\/10.1515\/pac-2018-1102","journal-title":"Pure Appl Chem"},{"key":"630_CR4","doi-asserted-by":"publisher","first-page":"11305","DOI":"10.1021\/cr500365f","volume":"114","author":"AS Nagle","year":"2014","unstructured":"Nagle AS, Khare S, Kumar AB et al (2014) Recent developments in drug discovery for leishmaniasis and human african trypanosomiasis. Chem Rev 114:11305. https:\/\/doi.org\/10.1021\/cr500365f","journal-title":"Chem Rev"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"9375","DOI":"10.1073\/pnas.0703678104","volume":"104","author":"J Luke\u0161","year":"2007","unstructured":"Luke\u0161 J, Mauricio IL, Sch\u00f6nian G et al (2007) Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci 104:9375\u20139380. https:\/\/doi.org\/10.1073\/pnas.0703678104","journal-title":"Proc Natl Acad Sci"},{"key":"630_CR6","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","volume":"5","author":"F Chappuis","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A et al (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5:873\u2013882. https:\/\/doi.org\/10.1038\/nrmicro1748","journal-title":"Nat Rev Microbiol"},{"key":"630_CR7","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1086\/318121","volume":"31","author":"S Sundar","year":"2000","unstructured":"Sundar S, More DK, Singh MK et al (2000) Failure of pentavalent antimony in visceral leishmaniasis in india: report from the center of the indian epidemic. Clin Infect Dis 31:1104\u20131107. https:\/\/doi.org\/10.1086\/318121","journal-title":"Clin Infect Dis"},{"key":"630_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1473-3099(10)70011-6","volume":"10","author":"J van Griensven","year":"2010","unstructured":"van Griensven J, Balasegaram M, Meheus F et al (2010) Combination therapy for visceral leishmaniasis. Lancet Infect Dis 10:184\u2013194. https:\/\/doi.org\/10.1016\/S1473-3099(10)70011-6","journal-title":"Lancet Infect Dis"},{"key":"630_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nchembio837","volume":"2","author":"AR Renslo","year":"2006","unstructured":"Renslo AR, McKerrow JH (2006) Drug discovery and development for neglected parasitic diseases. Nat Chem Biol 2:701\u2013710. https:\/\/doi.org\/10.1038\/nchembio837","journal-title":"Nat Chem Biol"},{"key":"630_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.2174\/138945009787581177","volume":"10","author":"A Cruz","year":"2009","unstructured":"Cruz A, de Toledo J, Falade M et al (2009) Current treatment and drug discovery against Leishmania spp. and Plasmodium spp. A review. Curr Drug Targets 10:178\u2013192. https:\/\/doi.org\/10.2174\/138945009787581177","journal-title":"Curr Drug Targets"},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S10020-018-0069-7","volume":"25","author":"AP de Porto","year":"2019","unstructured":"de Porto AP, Liu Z, de Beer R et al (2019) Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia. Mol Med 25:1\u201310. https:\/\/doi.org\/10.1186\/S10020-018-0069-7","journal-title":"Mol Med"},{"key":"630_CR12","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci 107:13075\u201313080. https:\/\/doi.org\/10.1073\/pnas.1004594107","journal-title":"Proc Natl Acad Sci"},{"key":"630_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z, Scheerens H, Li SJ et al (2007) Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem 2:58\u201361. https:\/\/doi.org\/10.1002\/cmdc.200600221","journal-title":"ChemMedChem"},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/nrc3702","volume":"14","author":"RW Hendriks","year":"2014","unstructured":"Hendriks RW, Yuvaraj S, Kil LP (2014) Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer 14:219\u2013232. https:\/\/doi.org\/10.1038\/nrc3702","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"630_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.687458","volume":"23","author":"IE Ahn","year":"2021","unstructured":"Ahn IE, Brown JR (2021) Targeting Bruton\u2019s tyrosine kinase in CLL. Front Immunol 23(12):687458. https:\/\/doi.org\/10.3389\/fimmu.2021.687458","journal-title":"Front Immunol"},{"key":"630_CR16","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1074\/jbc.m115.687251","volume":"291","author":"L Ren","year":"2016","unstructured":"Ren L, Campbell A, Fang H et al (2016) Analysis of the effects of the Bruton\u2019s tyrosine kinase (Btk) inhibitor Ibrutinib on monocyte Fc\u03b3 receptor (Fc\u03b3R) function. J Biol Chem 291:3043\u20133052. https:\/\/doi.org\/10.1074\/jbc.m115.687251","journal-title":"J Biol Chem"},{"issue":"11","key":"630_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-018-0136-x","volume":"8","author":"A Colado","year":"2018","unstructured":"Colado A, Genoula M, Cougoule C et al (2018) Effect of the BTK inhibitor ibrutinib on macrophage- and \u03b3\u03b4 T cell-mediated response against Mycobacterium tuberculosis. Blood Cancer J 8(11):1\u20136. https:\/\/doi.org\/10.1038\/s41408-018-0136-x","journal-title":"Blood Cancer J"},{"key":"630_CR18","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.3324\/haematol.2014.119669","volume":"100","author":"M Borge","year":"2015","unstructured":"Borge M, Almej\u00fan MB, Podaza E et al (2015) Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 100:e140\u2013e142. https:\/\/doi.org\/10.3324\/haematol.2014.119669","journal-title":"Haematologica"},{"key":"630_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fcimb.2012.00083","volume":"2","author":"D Liu","year":"2012","unstructured":"Liu D, Uzonna JE (2012) The early interaction of Leishmania with macrophages and dendritic cells and its influence on the host immune response. Front Cell Infect Microbiol 2:83. https:\/\/doi.org\/10.3389\/fcimb.2012.00083","journal-title":"Front Cell Infect Microbiol"},{"key":"630_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytox.2020.100041","volume":"2","author":"C Bogdan","year":"2020","unstructured":"Bogdan C (2020) Macrophages as host, effector and immunoregulatory cells in leishmaniasis: impact of tissue micro-environment and metabolism. Cytokine X 2:100041. https:\/\/doi.org\/10.1016\/j.cytox.2020.100041","journal-title":"Cytokine X"},{"key":"630_CR21","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/S10495-010-0569-6","volume":"16","author":"A Khare","year":"2010","unstructured":"Khare A, Viswanathan B, Gund R et al (2010) Role of Bruton\u2019s tyrosine kinase in macrophage apoptosis. Apoptosis 16:334\u2013346. https:\/\/doi.org\/10.1007\/S10495-010-0569-6","journal-title":"Apoptosis"},{"key":"630_CR22","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1182\/blood-2013-06-507947","volume":"122","author":"JA Dubovsky","year":"2013","unstructured":"Dubovsky JA, Beckwith KA, Natarajan G et al (2013) Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 122:2539\u20132549. https:\/\/doi.org\/10.1182\/blood-2013-06-507947","journal-title":"Blood"},{"key":"630_CR23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1093\/infdis\/jiy552","volume":"219","author":"S Varikuti","year":"2019","unstructured":"Varikuti S, Volpedo G, Saljoughian N et al (2019) The potent ITK\/BTK inhibitor Ibrutinib is effective for the treatment of experimental visceral Leishmaniasis caused by Leishmania donovani. J Infect Dis 219:599\u2013608. https:\/\/doi.org\/10.1093\/infdis\/jiy552","journal-title":"J Infect Dis"},{"key":"630_CR24","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","volume":"44","author":"D Szklarczyk","year":"2016","unstructured":"Szklarczyk D, Santos A, von Mering C et al (2016) STITCH 5: augmenting protein\u2013chemical interaction networks with tissue and affinity data. Nucleic Acids Res 44:D380. https:\/\/doi.org\/10.1093\/nar\/gkv1277","journal-title":"Nucleic Acids Res"},{"key":"630_CR25","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1182\/blood-2016-06-722900","volume":"129","author":"E Kim","year":"2017","unstructured":"Kim E, Hurtz C, Koehrer S et al (2017) Ibrutinib inhibits pre-BCR + B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood 129:1155\u20131165. https:\/\/doi.org\/10.1182\/blood-2016-06-722900","journal-title":"Blood"},{"issue":"9","key":"630_CR26","doi-asserted-by":"publisher","first-page":"691","DOI":"10.3390\/microorganisms9040691","volume":"27","author":"A Efstathiou","year":"2021","unstructured":"Efstathiou A, Smirlis D (2021) Leishmania protein kinases: important regulators of the parasite life cycle and molecular targets for treating Leishmaniasis. Microorganisms 27(9):691. https:\/\/doi.org\/10.3390\/microorganisms9040691","journal-title":"Microorganisms"},{"key":"630_CR27","doi-asserted-by":"publisher","first-page":"65968","DOI":"10.18632\/oncotarget.11782","volume":"7","author":"S Fiorcari","year":"2016","unstructured":"Fiorcari S, Maffei R, Audrito V et al (2016) Ibrutinib modifies the function of monocyte\/macrophage population in chronic lymphocytic leukemia. Oncotarget 7:65968. https:\/\/doi.org\/10.18632\/oncotarget.11782","journal-title":"Oncotarget"},{"key":"630_CR28","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.clim.2004.07.017","volume":"114","author":"D Nandan","year":"2005","unstructured":"Nandan D, Reiner NE (2005) Leishmania donovani engages in regulatory interference by targeting macrophage protein tyrosine phosphatase SHP-1. Clin Immunol 114:266\u2013277. https:\/\/doi.org\/10.1016\/j.clim.2004.07.017","journal-title":"Clin Immunol"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/J.1365-2249.2008.03741.x","volume":"154","author":"D Chandra","year":"2008","unstructured":"Chandra D, Naik S (2008) Leishmania donovani infection down-regulates TLR2-stimulated IL-12p40 and activates IL-10 in cells of macrophage\/monocytic lineage by modulating MAPK pathways through a contact-dependent mechanism. Clin Exp Immunol 154:224. https:\/\/doi.org\/10.1111\/J.1365-2249.2008.03741.x","journal-title":"Clin Exp Immunol"},{"issue":"7","key":"630_CR30","doi-asserted-by":"publisher","first-page":"14693","DOI":"10.1038\/s41598-017-14935-3","volume":"31","author":"C Terrazas","year":"2017","unstructured":"Terrazas C, Varikuti S, Oghumu S et al (2017) Ly6C hi inflammatory monocytes promote susceptibility to Leishmania donovani infection. Sci Res 31(7):14693. https:\/\/doi.org\/10.1038\/s41598-017-14935-3","journal-title":"Sci Res"}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-022-00630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11686-022-00630-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11686-022-00630-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T02:35:48Z","timestamp":1669689348000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11686-022-00630-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,19]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s11686-022-00630-5","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,19]]},"assertion":[{"value":"22 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was designed as an in vitro study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All authors gave consent for the data to be published in the journal article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate and for Publication"}},{"value":"None to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Transparency Declarations"}}]}}